A randomized, open-label, crossover comparison study for the effects of consumption of frozen dessert on blood glucose levels

A randomized, open-label, crossover comparison study for the effects of consumption of frozen dessert on blood glucose levels - A randomized, open-label, crossover comparison study for the effects of consumption of frozen dessert on blood glucose levels

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061018

Enrollment

Registered

2026-03-23

Start date

2026-03-23

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Control food -&gt

The test food1 -&gt

The test food2 *Take each test food over five min Control food -&gt

The test food2 -&gt

The test food1 *Take each test food over five min The test food1 -&gt

Control food *Take each test food over five min The test food1 -&gt

The test food2 *Take each test food over five min The test food2 -&gt

The test food1 *Take each test food over five min The test food2 -&gt

Control food *Take each test food over five min

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women aged 20 or more and less than 65 at the time of agreement to participate in this study

Exclusion criteria

Exclusion criteria: 1. Individuals whose fasting blood glucose level is 126 mg/dL or more at screening (Scr) 2. Individuals whose hemoglobin A1c (HbA1c) is 6.5% or more at Scr 3. Individuals who take medicines that may influence the blood glucose level 4. Individuals who are currently taking "Foods for Specified Health Uses" or "Foods with Function Claims" 5. Individuals who are undergoing medical treatment or have a serious medical history of any disease such as liver, kidney, heart, lung, digestive organ, blood, endocrine system, or metabolic system 6. Individuals who have drug allergy or food allergy (such as eggs, milk ingredients, soybeans) 7. Individuals who are pregnant, planning to become pregnant during this study, or lactating 8. Individuals who are collected 400 mL or more of blood due to blood donation within 8 weeks before the agreement to participate in this study 9. Individuals who are dental decay or hypersensitive teeth 10. Individuals who are participating in other clinical trials or plan to participate in another study during this study 11. Individuals who are judged as ineligible to participate in this study based on the results of participant' background, physical finding, consultation, physical examination, and clinical examination, by principal physician or sub-physician

Design outcomes

Primary

Measure	Time frame
1. Incremental Area Under the Curve (IAUC)120 min of blood glucose level	—

Secondary

Measure	Time frame
1. Blood glucose levels (blood glucose levels at each time point, the maximum blood concentration (Cmax), the time to maximum blood concentration (Tmax)) 2. Insulin (blood insulin levels at each time point, IAUC120 min, Cmax, Tmax) 3. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (GIP, GLP-1 at each point, IAUC120 min, Cmax, Tmax) 4. Adverse events and side effects	—

Measure

Time frame

1. Blood glucose levels (blood glucose levels at each time point, the maximum blood concentration (Cmax), the time to maximum blood concentration (Tmax)) 2. Insulin (blood insulin levels at each time point, IAUC120 min, Cmax, Tmax) 3. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (GIP, GLP-1 at each point, IAUC120 min, Cmax, Tmax) 4. Adverse events and side effects

—

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026